Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study to Evaluate Safety and Preliminary Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia

NCT07297550 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07297550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07297550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study to Evaluate Safety and Preliminary Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 15, 2025
Completion date
July 1, 2027
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed aplastic anemia, refractory aplastic anemia, severe aplastic anemia